Chemical Structure (Alendronate 35 mg For Teva 1)
Alendronate Sodium
Product Images NDC 33261-993
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 33261-993). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aidarex Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image Label (Alendronate 35 mg For Teva 10)
This is a medication packaging for Alendronate 35mg. The label indicates that the medication should not be dispensed without a prescription and should be kept out of reach of children. It should be stored at a controlled room temperature between 16-30 degrees Celsius (53-86 degrees Fahrenheit). The medication is manufactured by Aidarex Pharmaceuticals LLC and is a generic version of Fosamax. The active ingredient is Alendronate Sodium, and it is to be taken every 24 hours, once a day. The packaging contains four pills and the manufacturer is TEVA Pharmaceuticals USA, located in Sellersville, PA 18960.*
Figure 1 (Alendronate 35 mg For Teva 2)
Figure 2 (Alendronate 35 mg For Teva 3)
Figure 3 (top) (Alendronate 35 mg For Teva 4)
Figure 3 (bottom) (Alendronate 35 mg For Teva 5)
Figure 4 (top) (Alendronate 35 mg For Teva 6)
This text provides a chart showing the mean % change in bone mineral density (BMD) from baseline after a 2-year study of alendronate and placebo treatments. The chart includes measurements for the lumbar spine, femoral neck, trochanter, and total body.*
Figure 4 (bottom) (Alendronate 35 mg For Teva 7)
Figure 5 (Alendronate 35 mg For Teva 8)
Figure 6 (Alendronate 35 mg For Teva 9)
This is data on the mean percentage change from baseline of Senum Alkaline Phosphatase for different treatments over time (in months). The treatments include placebo, Eidronate at 400 mg/day, Multinational Study Aendronas at 40 mg/day, and US Study A Hendronate at 40 mg/day. However, there is not enough information to draw any conclusions from the data presented.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
